
Adams Revives Bally's Casino Bid by Vetoing Council's Vote to Block It
His move may help President Trump: If the company, Bally's, were to win approval, it would pay $115 million to the Trump Organization, the former operator of the site. Mr. Adams, however, cited a different objective, saying in a statement that by vetoing the Council's rejection of Bally's land-use application, he was creating an even playing field for all the contenders seeking casino licenses in the New York City area.
The City Council now has 10 days to override the mayor's veto with a two-thirds majority vote.
Mara Davis, a City Council spokeswoman, said in a statement that 'the mayor's words have no credibility' and that 'the Council will consider its next steps on this land-use application.'
The Council, following a tradition of abiding by local members' wishes on land-use matters, voted overwhelmingly against the necessary zoning change earlier this month. Kristy Marmorato, the Republican city councilwoman whose district includes the proposed Bronx site, has described the plan as a 'predatory development,' though the bid has won support from other Bronx elected officials. She had no immediate comment on Wednesday.
By the end of this year, New York State is poised to award up to three full-scale casino licenses in New York City and its environs, and the competition is fierce. There are bids to put casinos on Manhattan's West Side and East Side, as well as a Jay-Z-backed proposal for Times Square; there is a Queens proposal from the New York Mets owner Steven A. Cohen, another bid for Coney Island, and bids from two existing slot-machine venues at racetracks in Queens and Yonkers.
Mr. Adams, the former chair of the State Senate Committee on Racing, Gaming and Wagering, is an ardent supporter of bringing gambling to New York City.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
5 minutes ago
- Wall Street Journal
Stocks to Watch Tuesday: Palantir, BP, Pfizer
↗️ Palantir (PLTR): The data-software company's stock rose 5% premarket after it posted higher quarterly profit and revenue. It also boosted its annual outlook. ↘️ Vertex Pharmaceuticals (VRTX): The biotechnology company said it wouldn't proceed with advanced testing of an experimental painkiller. Vertex stock slid off-hours. ↗️ BP (BP): The energy company said a measure of profitability rose in the latest quarter and pledged more cost cuts. Shares rose in London.

Wall Street Journal
5 minutes ago
- Wall Street Journal
Global Markets Rise on Fed Rate-Cut Hopes
U.S. stock futures rose, tracking the higher close on Wall Street Monday after investors scooped up stocks at lower valuations following last week's falls. Also boosting sentiment, rising expectations that the Federal Reserve will cut interest rates in September as President Trump moves to make some key hires in the Fed's governing board and at the Bureau of Labor Statistics. Meanwhile, there's a new trade deadline on Thursday with some countries still racing to renegotiate tariffs. Switzerland, threatened with a 39% rate, said it is prepared to make concessions to lower it. Earnings today come from Fox, Pfizer and Kellogg, and later from News Corp, AMD and Amgen.

Wall Street Journal
5 minutes ago
- Wall Street Journal
Exclusive: White House to Target 'Debanking'
The White House plans to step up pressure against banks over perceived discrimination against conservatives and crypto companies, with an executive order that threatens to fine lenders that drop customers for political reasons. A draft of the order, which was viewed by The Wall Street Journal, directs regulators to investigate whether any financial institutions might have violated the Equal Credit Opportunity Act, antitrust laws or consumer financial protection laws. 🔎 Go deeper: